Kazakhstan vs Saint Kitts and Nevis: Hepatitis B surface antigen (HBsAg) prevalence
Kazakhstan
0.2%
in 2024
Saint Kitts and Nevis
0.2%
in 2024
Kazakhstan rank
82nd
Saint Kitts and Nevis rank
82nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Kazakhstan
- Saint Kitts and Nevis
How they compare
Kazakhstan currently reports 0.2% against 0.2% in Saint Kitts and Nevis, a difference of 0.0%.
Across all 10 years both countries report, Saint Kitts and Nevis has been ahead every year.
Kazakhstan ranks 82nd and Saint Kitts and Nevis ranks 82nd of 194 countries.
Saint Kitts and Nevis has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Saint Kitts and Nevis |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Kazakhstan or Saint Kitts and Nevis?
- Kazakhstan, at 0.2% against 0.2% in Saint Kitts and Nevis as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Kazakhstan and Saint Kitts and Nevis?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Saint Kitts and Nevis?
- 10 years are reported by both, from 2015 to 2024.
- How do Kazakhstan and Saint Kitts and Nevis rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Kazakhstan ranks 82nd and Saint Kitts and Nevis ranks 82nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.